Molecular Therapy · 2021 · 57 citations · 25 references
Life SciencesMolecular BiologyPharmacologyMolecular PharmacologyRenal PathophysiologyTranscriptomicsDiabetic Kidney DiseaseRenal DiseaseRenal PharmacologySingle-cell Rna Sequencing AnalysisSingle-cell TranscriptomicsSodium-glucose Cotransporter 2 InhibitorsGene Expression SignaturesKidney DiseasesProximal Tubular DysfunctionRenoprotective EffectsRenoprotective TherapiesSingle-cell Rna SequencingSodium-glucose CotransportSodium-glucose Cotransporter 2 Inhibition
Angiotensin receptor blockers (ARBs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been used as the standard therapy for patients with diabetic kidney disease (DKD). However, how these two drugs possess additive renoprotective effects remains unclear. Here, we conducted single-cell RNA sequencing to profile the kidney cell transcriptome of db/db mice treated with vehicle, ARBs, SGLT2i, or ARBs plus SGLT2i, using db/m mice as control. We identified 10 distinct clusters of kidney cells with predominant proximal tubular (PT) cells. We found that ARBs had more anti-inflammatory and anti-fibrotic effects, while SGLT2i affected more mitochondrial function in PT. We also identified a new PT subcluster, was increased in DKD, but reversed by the treatments. This new subcluster was also confirmed by immunostaining of mouse and human kidneys with DKD. Together, our study reveals kidney cell-specific gene signatures in response to ARBs and SGLT2i and identifies a new PT subcluster, which provides new insight into the pathogenesis of DKD.
25
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
Paul A. James, Suzanne Oparil, Barry L. Carter et al. · JAMA · 2013 · 8K citations
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 6K citations · Full text
Medicine, Nephrology, Pharmacology +17